Lipid nanoparticles (LNPs)

At their core, lipid nanoparticles are engineered carriers designed to solve a fundamental challenge in medicine: protecting fragile drug payloads and ensuring they reach their intended destination within the body. An LNP is typically 80 to 100 nanometers in diameter—far smaller than a human cell—and consists of a dense lipid core containing the therapeutic agent. This structure is meticulously designed with a specific mixture of lipids, each serving a distinct purpose. The key component is an ionizable cationic lipid, which is positively charged in an acidic environment, allowing it to bind and encapsulate negatively charged molecules like mRNA during manufacturing.

Once administered, the LNP's composition is critical for its journey through the bloodstream. A layer of PEGylated lipids (lipids attached to polyethylene glycol) forms a hydrophilic, protective "stealth" coating that helps the nanoparticle evade detection by the immune system and prolongs its circulation time. Other components, such as cholesterol and helper phospholipids, provide structural integrity and stability to the particle. Upon reaching a target cell, the LNP is taken up into a compartment called an endosome. The acidic environment inside the endosome causes the ionizable lipid to regain its positive charge, which disrupts the endosomal membrane and allows the therapeutic payload to be released into the cell's cytoplasm, where it can perform its function.

Lipid nanoparticles are a leading platform technology within the broader fields of nanomedicine and drug delivery. For decades, scientists have sought safe and effective ways to deliver genetic material into cells, a field historically dominated by viral vectors (modified, non-infectious viruses). While viral vectors are effective, they can sometimes trigger strong immune responses and carry a small risk of integrating into the host's genome. LNPs emerged as a promising non-viral alternative, offering advantages such as lower immunogenicity, simpler and more scalable manufacturing processes, and the ability to deliver repeated doses. The technology matured over several decades, culminating in the 2018 approval of Onpattro (patisiran), the first siRNA-based drug delivered via LNPs for treating a rare genetic disease.

The global significance of lipid nanoparticles was cemented during the COVID-19 pandemic, as they are the essential delivery system for the two leading mRNA vaccines from Pfizer-BioNTech and Moderna. Without the protective and cell-penetrating capabilities of LNPs, the fragile mRNA molecules in the vaccines would be rapidly degraded by enzymes in the body and would be unable to enter cells to instruct them to produce the viral spike protein that elicits an immune response. This success has transformed LNPs from a niche technology into a cornerstone of modern vaccinology and therapeutics. Looking forward, the versatility of the LNP platform holds immense promise for a new generation of medicines, including personalized cancer vaccines, gene-editing therapies using CRISPR, and treatments for a wide range of genetic, metabolic, and infectious diseases.